koko体育app

欢迎来到《koko体育app 学报（医学版）》
陈晓曦, 袁粒星, 张鸽等. koko体育app 急性B前体淋巴细胞白血病CD20表达与临床特征及预后的相关性研究[J]. koko体育app 学报（医学版）, 2014, 45(4): 658-663.
引用本文: 陈晓曦, 袁粒星, 张鸽等. koko体育app 急慢性B前体淋巴腺神经元败血症CD20表现与临床上显著特点及效果的相关的性科研[J]. 北京大专学报（分子生物学版）, 2014, 45(4): 658-663.
CHEN Xiao-xi, YUAN Li-xing, ZHANG Ge. et al. Expression of CD20 in B-cell Precursor Acute Lymphoblastic Leukemia and Its Correlation with Clinical Outcomes[J]. Journal of Sichuan University (Medical Sciences), 2014, 45(4): 658-663.
Citation: CHEN Xiao-xi, YUAN Li-xing, ZHANG Ge. et al. Expression of CD20 in B-cell Precursor Acute Lymphoblastic Leukemia and Its Correlation with Clinical Outcomes[J]. Journal of Sichuan University (Medical Sciences), 2014, 45(4): 658-663.

koko体育app 急性B前体淋巴细胞白血病CD20表达与临床特征及预后的相关性研究

Expression of CD20 in B-cell Precursor Acute Lymphoblastic Leukemia and Its Correlation with Clinical Outcomes

  • 摘要: 目的 探讨CD20表达与koko体育app 急性B前体淋巴细胞白血病（BCP-ALL）临床特征和预后的关系。方法 研究对象为我院2009年1月至2013年5月收治的271例初诊koko体育app BCP-ALL，统一按中国koko体育app 白血病协作组ALL 2008方案规范化分型治疗并长期随访。统计分析CD20阳性（CD20+BCP）和CD20阴性（CD20-BCP）ALL的临床特征、早期治疗反应和预后情况。结果 CD20+BCP占本组BCP-ALL的45.76%（124例）。CD20+BCP与CD20-BCP在性别构成比、初诊中位年龄、初诊外周血白细胞中位计数、泼尼松不敏感比例和临床危险度病例分布的差异均无统计学意义（P均>0.05）。CD20+BCP和CD20-BCP组中≥10岁的病例分别占25.81%和14.29%（P=0.017），pro-B和pre-B病例比例分别为43.55%、59.86%和56.45%、40.14%（P=0.007），BCR-ABL阳性病例比例分别为12.20%和4.86％（P=0.03），TEL-AML1阳性病例比例分别为6.50％和18.06％（P=0.005）。两组患儿诱导化疗第15 d和第33 d骨髓完全缓解率分别为77.50%（93／120）和74.13%（106／143），95.04%（115／121）和95.83%（138／144）（P均>0.05），4年无事件生存（EFS）率分别为78.00%±4.96%和79.05%±5.40%，4年总生存（OS）率分别为83.01%±6.13%和93.64%±2.46%（P均>0.05）。结论 CD20阳性表达与koko体育app BCP-ALL预后无明确相关性，尚不能作为判断koko体育app BCP-ALL不良预后的指标。CD20靶向免疫治疗在koko体育app BCP-ALL的应用尚需深入研究。  
    Abstract: Objective To determine whether expression of CD20 is associated with clinical outcomes of childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Methods 271 newly diagnosed childhood BCP-ALL during January 2009 to May 2013 were enrolled in this study.The patients were treated in line with the Chinese Childhood Leukemia Group ALL 2008 protocol (CCLG-ALL 2008). The clinical feature, early therapeutic response and clinical outcomes of the patients with a CD20 positive (CD20+BCP) expression were compared with those with a CD20 negative (CD20-BCP) expression. Results CD20+BCP accounted for 45.76% (124 cases) of all participants. There were no significant differences between CD20+BCP and CD20-BCP patients in gender distribution, age,WBC counts when diagnosis was made, proportion of prednisone poor responders, and distribution of risk categories (P>0.05). Patients of 10 years or older comprised 25.81% and 14.29% of CD20+BCP and CD20-BCP patients, respectively (P=0.017). Pro-B and pre-B cases accounted for 43.55% and 59.86% of CD20+BCP patients respectively, compared with 56.45 and 40.14% in CD20-BCP patients (P=0.007). CD20+BCP patients had 12.20% Philadelphia positive ALL and 6.50% BCP-ALL with TEL-AML1 fusion gene,compared with 4.86%(P=0.03) and 18.06% (P=0.005) in those of CD20-BCP. No significant differences were found between the two groups of patients in 15-day (77.50% vs. 74.13%, P=0.525) and 33-day (95.04% vs. 95.83%, P=0.757) complete remission rates. No significant differences (P>0.05) were found in predicted 4-year event-free survival 〔EFS (78.00%±4.96%) vs. (79.05%±5.40%)〕 and predicted 4-year overall survival 〔OS (83.01%±6.13%) vs. (93.64%±2.46%)〕 between the two groups of patients either. Conclusion CD20 positivity was not found to be associated with worse prognosis of children with BCP-ALL. More studies are needed to validate the correlation between CD20 and unfavorable outcomes in BCP-ALL.  
    • HTML全文
© 2014 《koko体育app 学报（医学版）》编辑部　版权所有 cc

开放获取🥃 本文遵循知识共享署名—非商业性使用4.0国际许可协议（CC BY-NC 4.0），允许第三方对本刊发表的论文自由共享（即在任何媒介以任何形式复制、发行原文）、演绎（即修改、转换或以原文为基础进行创作），必须给出适当的署名，提供指向本文许可协议的链接，同时标明是否对原文作了修改；不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问

/

返回文章
返回
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"}); koko体育-koko体育app koko体育-koko体育网页版koko体育app koko体育-全站app下载(官网) m6米乐app|下载 m6米乐app|主頁欢迎您!!